PDRN
A salmon-DNA-derived polynucleotide that accelerates wound healing and skin rejuvenation through adenosine A2A receptor activation.
PDRN (Polydeoxyribonucleotide) is a biotechnological compound derived from salmon sperm DNA (Oncorhynchus mykiss) through extraction, purification, and fractionation, consisting of polynucleotide chains with molecular weights ranging from 50 to 1500 kDa. It is widely used in Asian aesthetic medicine, particularly South Korea, for skin rejuvenation, wound healing, and hair loss treatment. Its mechanism centers on adenosine A2A receptor activation, which stimulates collagen synthesis, cellular proliferation, angiogenesis, and anti-inflammatory pathways. PDRN is one of the few compounds in its class with a substantial published clinical (Phase 4) evidence base in aesthetic applications.
Class
Biotechnological polynucleotide (salmon DNA-derived)
Half-life
Short (oligonucleotides degraded rapidly; tissue effects persist longer)
Routes
Subcutaneous, Intradermal, Topical
Category
Healing & Recovery
Researched benefits
What it's studied for
Wound healing acceleration
PDRN enhances angiogenesis, fibroblast proliferation, and collagen synthesis to speed tissue repair. These effects are driven by adenosine A2A receptor agonism stimulating VEGF production and cellular proliferation.
Skin rejuvenation
Multiple randomized controlled trials demonstrate improved skin texture and elasticity following PDRN treatment. It is a mainstay of aesthetic skin protocols in Korean clinical practice.
Diabetic ulcer healing
PDRN has high-quality clinical (Phase 4) evidence supporting improved healing of diabetic foot ulcers, reflecting its combined angiogenic and anti-inflammatory actions.
Androgenetic alopecia
Clinical evidence supports hair follicle stimulation via A2A receptor activation, positioning PDRN as an adjunct in hair loss treatment.
Anti-inflammatory tissue remodeling
PDRN reduces pro-inflammatory cytokines, shifting the local environment toward regeneration rather than chronic inflammation.
Aesthetic skin treatments
PDRN is widely used in Korean skin medicine clinical practice for overall skin quality, hydration, and rejuvenation, with an established tolerability profile.
Mechanism
How it works
PDRN exerts its effects through two primary mechanisms. The first is adenosine A2A receptor agonism: PDRN is progressively hydrolyzed to deoxyadenosine fragments that activate A2A receptors on fibroblasts, endothelial cells, and macrophages. A2A activation stimulates VEGF production (driving angiogenesis), collagen synthesis, and cellular proliferation while dampening pro-inflammatory signaling.
The second mechanism is the salvage pathway. The nucleotides and nucleosides released as PDRN degrades supply purine and pyrimidine building blocks that cells reuse for DNA synthesis and energy metabolism, supporting proliferation in tissues undergoing repair.
Together, these actions promote angiogenesis, fibroblast activity, and extracellular matrix (collagen) deposition while reducing pro-inflammatory cytokine levels, producing the wound-healing, skin-rejuvenating, and anti-inflammatory tissue-remodeling effects observed in clinical practice.
Dosing protocols
Dosing & administration
Dosing reflects protocols reported in research and community literature for educational purposes. It is not medical advice or a recommendation. Most peptides here are not approved for human use.
Aesthetic / clinical
- Dose
- Not specified in source
- Frequency
- Typically weekly
- Timing
- Per clinical protocol
- Duration
- Course of treatments
- Route
- Subcutaneous, intradermal, or topical
PDRN is most commonly administered on a weekly schedule in aesthetic and wound-care settings. Specific per-session dosing was not disclosed in the available source; injectable use should follow qualified clinical protocols.
- Dosing is typically weekly in aesthetic and wound-healing applications.
- Injectable PDRN (e.g., Placentex Integro) is administered by qualified practitioners; topical formulations are used for at-home skin care.
- Specific mcg/mg dosing figures were gated in the available source and are therefore omitted rather than estimated.
Safety
Side effects & considerations
Commonly reported effects
Contraindications & cautions
- Known allergy or hypersensitivity to salmon-derived products
Because PDRN is derived from salmon DNA, there is a risk of allergic reaction in sensitive individuals. No serious systemic adverse events have been reported in published aesthetic medicine RCTs. Formal interaction and contraindication data are still being compiled.
FAQ
PDRN — common questions
What is PDRN used for in research?
PDRN is a salmon-DNA-derived polynucleotide widely used in Asian aesthetic medicine for skin rejuvenation, wound healing, and hair loss treatment. Its mechanism centers on adenosine A2A receptor activation, which stimulates collagen synthesis, cellular proliferation, and anti-inflammatory pathways. It has a substantial published clinical (Phase 4) evidence base in aesthetic applications.
Where does PDRN come from?
PDRN is derived from salmon sperm DNA (Oncorhynchus mykiss) through extraction, purification, and fractionation. The resulting polynucleotide chains have molecular weights ranging from 50 to 1500 kDa.
How is PDRN administered?
PDRN is used subcutaneously, intradermally, and topically. It is available as an injectable sterile solution (Placentex Integro) licensed in several countries, as well as in topical formulations and cosmetic creams.
How does PDRN work?
PDRN is hydrolyzed to deoxyadenosine fragments that activate adenosine A2A receptors on fibroblasts, endothelial cells, and macrophages, stimulating VEGF-driven angiogenesis, collagen synthesis, and anti-inflammatory signaling. Its degradation products also feed the salvage pathway, supplying nucleotides for cellular repair.
Is PDRN safe?
PDRN is generally well tolerated in aesthetic clinical literature, with common effects limited to mild injection site bruising, swelling, and transient redness. Because it is salmon-derived, there is a risk of allergic reaction, though no serious systemic adverse events have been reported in published aesthetic RCTs.
What conditions has PDRN been studied for?
PDRN has clinical evidence supporting wound healing acceleration, skin rejuvenation, diabetic ulcer healing (Phase 4), androgenetic alopecia, and anti-inflammatory tissue remodeling.
